Acta dermato-venereologica最新文献_第2页

Spontaneous Regression of a Verrucous Venous Malformation Associated with a Previously Undescribed MAP3K3 Variant. 与先前未描述的MAP3K3变异相关的疣状静脉畸形的自发消退。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-10-06 DOI: 10.2340/actadv.v105.44095

Andrea Diociaiuti, Emanuele Bellacchio, Claudia Cesario, Sabrina Rossi, Giovanna Zambruno, May El Hachem

引用次数: 0

The Epidemiology of Chronic Prurigo: Lessons Learned. 慢性痒疹的流行病学：经验教训。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-10-03 DOI: 10.2340/actadv.v105.44334

Maurice Waitek, Elke Weisshaar

引用次数: 0

Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations. Dupilumab治疗特殊人群特应性皮炎的安全性和有效性分析。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-10-02 DOI: 10.2340/actadv.v105.43523

Niccolo Gori, Alvise Sernicola, Elena Ippoliti, Rosa Coppola, Martina Maurelli, Michela Ortoncelli, Claudia Paganini, Ersilia Tolino, Maria Mariano, Ester Del Duca, Gaia Moretta, Vincenzo Panasiti, Giampiero Girolomoni, Simone Ribero, Luisa Boeti, Luca Bianchi, Maria Concetta Fargnoli, Giovanni Pellacani, Sabatino Pallotta, Ketty Peris, Marco Galluzzo

{"title":"Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations.","authors":"Niccolo Gori, Alvise Sernicola, Elena Ippoliti, Rosa Coppola, Martina Maurelli, Michela Ortoncelli, Claudia Paganini, Ersilia Tolino, Maria Mariano, Ester Del Duca, Gaia Moretta, Vincenzo Panasiti, Giampiero Girolomoni, Simone Ribero, Luisa Boeti, Luca Bianchi, Maria Concetta Fargnoli, Giovanni Pellacani, Sabatino Pallotta, Ketty Peris, Marco Galluzzo","doi":"10.2340/actadv.v105.43523","DOIUrl":"10.2340/actadv.v105.43523","url":null,"abstract":"Dupilumab, the first biologic treatment approved for moderate to severe atopic dermatitis, has completely revolutionized the management of such disease allowing long-term control of its clinical signs and symptoms. Nevertheless, data regarding the safety and effectiveness profile of dupilumab in patients belonging to special populations are scarce. This observational, multicentric study analysed the effectiveness and safety profile of dupilumab over 3 years in the treatment of 70 patients with moderate to severe atopic dermatitis and associated comorbidities such as cancers, renal and liver failure, viral chronic infections, and degenerative and autoimmune neurological disorders. Patients achieved a significant improvement in both physician-assessed and patient-reported outcomes after 16 weeks of treatment, with a continuous therapeutic response maintained throughout the 156-week period. The safety profile was comparable to clinical trials and real-world data involving patients without significant comorbidities. In conclusion, the findings support the safety of dupilumab in managing severe atopic dermatitis in fragile patients.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43523"},"PeriodicalIF":3.7,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12504992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Features and Outcomes of Locally Advanced and Metastatic Basal Cell Carcinoma. 局部晚期和转移性基底细胞癌的临床特征和预后。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-10-02 DOI: 10.2340/actadv.v105.43240

Anna A J H Zwanenburg, Winan J Van Houdt, A Marjolein Schrijver, Willem H Schreuder, Michel W J M Wouters, Elsemieke I Plasmeijer

{"title":"Clinical Features and Outcomes of Locally Advanced and Metastatic Basal Cell Carcinoma.","authors":"Anna A J H Zwanenburg, Winan J Van Houdt, A Marjolein Schrijver, Willem H Schreuder, Michel W J M Wouters, Elsemieke I Plasmeijer","doi":"10.2340/actadv.v105.43240","DOIUrl":"10.2340/actadv.v105.43240","url":null,"abstract":"Cutaneous basal cell carcinoma (BCC) is a primarily indolent tumour that is easily cured. However, locally advanced BCC (laBCC) and metastatic BCC can have a poor prognosis. This retrospective cohort study, conducted at a single cancer centre over a 32-year period, reports the characteristics and clinical course of 51 patients with laBCC or metastatic BCC. Thirty-five patients were men (69%), with a mean age of 72 years. Most primary BCCs were located in the head and neck (59%), and were treated with surgery (78%). Thirty-four patients had laBCC; 6 of those developed subsequent metastasis. Twenty-three metastatic BCCs were included. The median size of laBCC was 73 mm (IQR 110; range 15-400 mm), with 71% measuring 5 cm or larger. Tumour infiltration beyond the subcutaneous fat was present in 59% of laBCC and bone infiltration in 12%. Of laBCC, 44% experienced local recurrence after resection, which was seen in 35% of local tumours later developing metastasis. Median time to metastasis was 33 months. Most patients developed nodal metastases only (70%), but 26% developed distant metastases. Fifteen patients died during follow-up (29%). Three patients died of their laBCC with a 5-year disease-specific survival of 79%. Five-year disease-specific survival for metastatic BCC was 30%. Patients with laBCC in this cohort were at high risk of local recurrence and metastasis, and 12% died of their laBCC. These findings highlight the need for intensified follow-up for this relatively rare population, especially since Hedgehog inhibitors and PD1 inhibitors might be available for these patients.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43240"},"PeriodicalIF":3.7,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12504993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cutaneous Graft-Versus-Host Disease Lichen Spinulosus-like: a New Form of Presentation of an Old Entity. 皮肤移植物抗宿主病棘样地衣：旧实体的新表现形式。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-09-30 DOI: 10.2340/actadv.v105.44373

Andrés Vidal González, Laura Taboada Paz, Sergio López Alcázar, Luis Requena Caballero, Marta Feito Rodríguez

引用次数: 0

Multiple Papules and Nodules in a Dermatomal Distribution: A Quiz. 皮肤分布中的多发丘疹和结节：一个小测验。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-09-29 DOI: 10.2340/actadv.v105.43203

Roberto Russo, Ilaria Salvi, Antonio Guadagno, Aurora Parodi, Emanuele Cozzani

引用次数: 0

Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte ratio, and Lymphocyte- to-Monocyte Ratio in Extramammary Paget's Disease: A Retrospective Study. 乳腺外佩吉特病的预处理中性粒细胞与淋巴细胞比率、血小板与淋巴细胞比率和淋巴细胞与单核细胞比率：回顾性研究。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-09-25 DOI: 10.2340/actadv.v105.43655

Wen-Hsin Yu, Che-Chia Hsu, Yi-Hua Liao, Chia-Yu Chu, Yi-Shuan Sheen

引用次数: 0

Preferences of Dermato-oncologists for Adjuvant Therapy in Stage II Melanoma: A Nationwide Discrete Choice Experiment. 皮肤肿瘤学家对II期黑色素瘤辅助治疗的偏好：一项全国性的离散选择实验。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-09-25 DOI: 10.2340/actadv.v105.44135

Amelie Kraaz, Wiebke K Peitsch, Laura Ratusznik, Katharina Diehl, Christian Kromer, Dilan Akbarzadeh, Marthe-Lisa Schaarschmidt, Juliane Weilandt

{"title":"Preferences of Dermato-oncologists for Adjuvant Therapy in Stage II Melanoma: A Nationwide Discrete Choice Experiment.","authors":"Amelie Kraaz, Wiebke K Peitsch, Laura Ratusznik, Katharina Diehl, Christian Kromer, Dilan Akbarzadeh, Marthe-Lisa Schaarschmidt, Juliane Weilandt","doi":"10.2340/actadv.v105.44135","DOIUrl":"10.2340/actadv.v105.44135","url":null,"abstract":"Adjuvant treatment decisions in stage IIB/C melanoma require careful weighing of benefits and risks. Our aim was to investigate how dermato-oncologists in Germany prioritize efficacy, toxicity, and application mode of modern adjuvants in these stages. In a nationwide discrete choice experiment physicians evaluated hypothetical treatment scenarios that varied in recurrence risk, risk of severe adverse events, type of adverse events, and mode of administration. Two patient profiles were presented, including a 55-year-old healthy patient in stage IIB (P1) and an 83-year-old patient in stage IIC with comorbidity (P2). Physicians (n = 112) preferred adjuvant therapy to the opt-out option in 86.4% of scenarios for P1 and in 60.5% for P2. The risk of severe adverse events was considered most important for both patients and significantly more relevant for P2 (relative importance score (RIS) 53.6 vs 40.2, p < 0.001), while recurrence risk was more relevant for P1 (RIS 36.3 vs 21.8, p < 0.001). Immune-related adverse events were less acceptable than gastrointestinal symptoms or pyrexia. Infusions at longer intervals were favoured compared with oral therapies. In conclusion, dermato-oncologists prioritized safety over efficacy, particularly in the older, comorbid patient. These preferences should be reconciled with patients' preferences and treatment goals during shared decision-making.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv44135"},"PeriodicalIF":3.7,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antihypertensive Medication as a Risk Factor For Basal Cell Carcinoma: A Nationwide Registry-based Case-control Study. 抗高血压药物是基底细胞癌的危险因素：一项基于全国登记的病例对照研究

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-09-23 DOI: 10.2340/actadv.v105.42749

Johan Kappelin, Ingela Ahnlide, Gustav B Christensen, Åsa Ingvar, Kari Nielsen

{"title":"Antihypertensive Medication as a Risk Factor For Basal Cell Carcinoma: A Nationwide Registry-based Case-control Study.","authors":"Johan Kappelin, Ingela Ahnlide, Gustav B Christensen, Åsa Ingvar, Kari Nielsen","doi":"10.2340/actadv.v105.42749","DOIUrl":"10.2340/actadv.v105.42749","url":null,"abstract":"Hydrochlorothiazide has been associated with increased cutaneous squamous cell carcinoma risk. Meanwhile, its association with basal cell carcinoma (BCC) risk is controversial. The association between commonly prescribed antihypertensive medications and BCC risk in the Swedish population was investigated. All cases with a histopathologically verified BCC in Sweden during 2007-2017 and 2 matched controls per case were included in this nationwide, registry-based, case-control study. Information on prescribed anti-hypertensive drugs, comorbidities, co-medications, and socioeconomic factors was retrieved from nationwide registries. The odds of being treated with any of the chosen treatments in relation to BCC diagnosis were estimated. In total, 133,539 cases and 257,849 controls were studied. Thiazide-containing combination treatments (OR 1.09), angiotensin II receptor blockers (OR 1.09), calcium channel blockers (OR 1.09), and beta-blockers (OR 1.07) were associated with an increased BCC risk. Use of single-agent thiazide treat-ment did not affect BCC risk. In conclusion, statistically significant associations were found between several commonly prescribed antihypertensives and an increased BCC risk. Thiazide treatment affected BCC risk only when given as combination treatment, indicating that relevant adjunctive substances should be studied further in relation to BCC risk. Presently, it is suggested that prevention efforts focus on UV protection rather than altering antihypertensive treatments.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42749"},"PeriodicalIF":3.7,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145123781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term Durability of Narrowband Ultraviolet B-induced Repigmentation in Non-segmental Vitiligo: A Retrospective Study. 窄带紫外线b诱导非节段性白癜风色素沉着的长期持久性：一项回顾性研究。

IF 3.7 4区医学

Acta dermato-venereologica Pub Date : 2025-09-23 DOI: 10.2340/actadv.v105.43690

Riad Kassem, Ilya Vaynshteyn, Aviv Barzilai, Assaf Handelsman, Alon Scope, Moshe Schaffer, Sharon Baum, Felix Pavlotsky

{"title":"Long-term Durability of Narrowband Ultraviolet B-induced Repigmentation in Non-segmental Vitiligo: A Retrospective Study.","authors":"Riad Kassem, Ilya Vaynshteyn, Aviv Barzilai, Assaf Handelsman, Alon Scope, Moshe Schaffer, Sharon Baum, Felix Pavlotsky","doi":"10.2340/actadv.v105.43690","DOIUrl":"10.2340/actadv.v105.43690","url":null,"abstract":"Narrowband ultraviolet B (NB-UVB) phototherapy is a well-established vitiligo treatment. However, limited data exist on the long-term effects of NB-UVB-induced repigmentation. This study evaluated the long-term durability of repigmentation achieved through NB-UVB phototherapy for up to 1 year in 176 patients with non-segmental vitiligo. Demographic and clinical variables, including age, gender, skin phototype, body site involvement, treatment duration, cumulative radiation dose, and clinically significant repigmentation response, were collected. Clinically significant repigmentation was defined as ≥ 50% repigmentation of vitiligo-affected areas, while a durable response was repigmentation lasting ≥ 6 months post-treatment. Of the 176 patients, 80 (45%) achieved clinically significant repigmentation, with the highest success rates observed in the face and neck region (53%). Among responders, 76 (95%) patients maintained their response for ≥ 6 months post-treatment discontinuation, and 47 (59%) sustained repigmentation for > 72 months. Additionally, ≥ 50% repigmentation, longer treatment duration (> 18 months), and higher cumulative radiation dose (> 356 J/cm²) were associated with a durable repigmentation response. NB-UVB phototherapy provides lasting repigmentation in non-segmental vitiligo, with many patients maintaining results for > 6 years. Clinically significant response post-NB-UVB phototherapy, prolonged treatment duration, and cumulative radiation dose are key factors associated with long-term repigmentation.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43690"},"PeriodicalIF":3.7,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145123787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0